PGN 650 I-124Alternative Names: 124I-PGN 650; PGN 650; PGN-650-124-I; PGN-650-I124
Latest Information Update: 26 May 2016
At a glance
- Originator Affitech A/S; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
- Developer Peregrine Pharmaceuticals
- Class Diagnostic agents; Imaging agents; Monoclonal antibody diagnostics
- Mechanism of Action Radionuclide imaging enhancers; Tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Solid tumours